Experimental analysis of behavior and tobacco regulatory research on nicotine reduction
Your everyday reinforcement tests can feed FDA nicotine rules—behavior analysts belong in tobacco policy rooms.
01Research in Context
What this study did
Bevins et al. (2018) wrote a position paper. They told the FDA to use behavior-analytic data when setting nicotine limits in cigarettes.
The authors explained how reinforcement thresholds work. They said operant lab methods can find the lowest nicotine dose that still rewards smokers.
The paper is a roadmap. It shows how BCBAs can give regulators numbers that save lives.
What they found
The paper does not report new lab data. Instead, it argues that threshold data are missing from tobacco policy.
Without these data, the FDA may set limits too high or too low. Either mistake keeps addiction going.
How this fits with other research
Normand et al. (2021) widens the same idea. They say ABA should guide all public-health rules, not just nicotine.
Napolitano et al. (2025) turns the plea into a plan. They want every state ABA group to hire policy staff.
Ghaziuddin (2000) set the stage. That paper told behavior analysts to build tech for outside users—exactly what Bevins et al. ask for with FDA.
Why it matters
You already run reinforcement assessments. Ask your clinic director to share de-identified threshold data with state health boards. Those numbers can back nicotine-cap proposals. One email from you adds real behavior-analytic evidence to the rule-making folder.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Strip client info from your last five progressive-ratio graphs and email them to your state health department tobacco-control officer.
02At a glance
03Original abstract
With the signing of H.R. 1256, the Family Smoking Prevention and Tobacco Control Act, the United States Food and Drug Administration (FDA) gained regulatory authority over the tobacco industry. A notable clause in this Act permits the FDA to regulate nicotine yields. However, they cannot completely remove this addictive constituent from tobacco products. This restriction has prompted the FDA to seek research on the threshold dose of nicotine that does not support dependence. This idea of threshold dose has led to an interesting reframing of scientific questions. For example, some researchers studying nicotine from this regulatory perspective translated the notion of an addiction threshold to a construct thought to play a role in addiction but which can be more readily operationalized. Examples include reinforcement threshold, discrimination threshold, and reinforcer-enhancement threshold. In this Perspective Paper, we highlight the importance of behavioral pharmacology and, specifically, the experimental analysis of behavior to help establish a scientific basis for policy decisions regarding nicotine yields. Recent research, including exemplars provided herein, note vast individual differences in the effects of nicotine at a known dose. Unfortunately, the behavioral and biological factors that contribute to such individual variations remain to be understood. We believe that behavior analysts are uniquely well-positioned to contribute to this understanding.
Journal of the Experimental Analysis of Behavior, 2018 · doi:10.1002/jeab.439